• Categories:News
• Author:
• Origin:
• Time of issue:2021-02-05 15:19
• Views:

(Summary description) Literature title: Incidence and predictors for cardiovascular events in patients with psoriatic arthritis.     Literature source: Ann Rheum Dis 2015 Oct 22     To assess the incidence and risk factors for cardiovascular events in patients with psoriatic arthritis (PsA). Researchers conducted a cohort study in which subjects were recruited from a large psoriatic arthritis (PsA) hospital for a follow-up survey between 1978-2013. Participants did assessments at 6-12 month intervals according to a standard protocol.     Information collected included demographics, lifestyle habits, medical history, medication use history, and outcomes associated with psoriatic arthritis (PsA). The primary outcome was a composite of primary cardiovascular endpoints, including myocardial infarction, ischemic stroke, angioplasty, and cardiovascular death. The association between characteristics of disease activity and the occurrence of cardiovascular events was assessed using a Cox proportional risk model.     Researchers analyzed 1091 cases of prostate-specific antigen. During the follow-up period, a total of 104 cardiovascular events occurred. A significant proportion of patients had a cardiovascular event (19.8% of patients, aged 70 years; 30.1%, aged 80 years). In the last decades (from 1978-2013), no trend in the presence of cardiovascular events was observed (p=0.73). In multivariate analysis, the following variables were independent predictors of major cardiovascular events: hypertension (relative risk ratio (RR) 1.81,P = 0.015), diabetes mellitus (RR 2.72,P<0.001) and number of finger shapes (RR 1.20,P<0.001). Sedimentation rate was a significant predictor for female patients only (RR = 1.83,P = 0.02).     Patients with psoriatic arthritis had a significant increase in cardiovascular events during the disease progression. The increased cardiovascular risk correlated with traditional cardiovascular risk factors and disease activity.           We produce APIs and intermediates for the treatment of psoriasis, Apoest and Apoest intermediates, if you need them, please feel free to contact us!